National survey on status of steroid therapy for cardiac sarcoidosis in Japan

Sarcoidosis Vasc Diffuse Lung Dis. 2005 Oct;22(3):210-3.

Abstract

Aim: This investigation was undertaken to clarify the current status of steroid therapy for cardiac sarcoidosis in Japan.

Methods: A questionnaire survey was conducted throughout Japan concerning cases in which steroid therapy had been administered. Replies describing 52 cases (15 men, 37 women; mean age +/- SD, 59.8 +/- 14.5 years) were analyzed.

Results: Of the 49 patients whose New York Heart Association (NYHA) functional classification was reported, 29 (55.8%) were in class I; 13 (25.0%) class II; 4 (7.7%) class III and 3 (5.8%) class IV. The most common initial steroid dose (used in 35 cases, or 67.3%) was 30 mg/day or 60 mg on alternate days. In most cases (85.4%), this dose was continued for 1 month followed by tapering by 5 mg every 2 to 4 weeks until reaching the maintenance dose of 5 to 10 mg/day. Steroid therapy was reported to result in improvement in 54%, no change in 40%, and deterioration in 6%.

Conclusion: This nationwide questionnaire survey indicated fairly uniform patterns of steroid therapy for cardiac sarcoidosis in Japan, with clinical improvement in over one-half of cases and possible stabilization in most others.

MeSH terms

  • Adult
  • Aged
  • Cardiomyopathies / classification
  • Cardiomyopathies / drug therapy*
  • Drug Administration Schedule
  • Female
  • Glucocorticoids / administration & dosage
  • Glucocorticoids / therapeutic use
  • Health Care Surveys
  • Heart Block / etiology
  • Humans
  • Japan
  • Male
  • Middle Aged
  • Prednisolone / administration & dosage
  • Prednisolone / therapeutic use*
  • Sarcoidosis / classification
  • Sarcoidosis / drug therapy*

Substances

  • Glucocorticoids
  • Prednisolone